GlobalData on MSN17d
Semaglutide shortage ends as FDA sets deadline for compoundersWith Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions are no longer allowed – for now.
Novo Nordisk has been busy scaling its manufacturing ... limelight earlier this month with its controversial Super Bowl advert – offers compounded semaglutide. Shares in the company tumbled ...
Exclusive: ASA calls number of parallel probes ‘significant’ and describes tackling issue as ‘priority’ after it issued warning to advertisers for drugs including Ozempic and Wegovy ...
We also treat our community members to special offers, promotions, and adverts from us and our partners ... The Independent A spokesperson for Novo Nordisk, the maker of Ozempic, Rybelsus ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results